Page 118 - Drug Class Review
P. 118

Page 89 of 205
             Drug Effectiveness Review Project
                                                 To evaluate efficacy and safety of DON at 5 mg/d in patients with mild to moderate AD over 24 weeks






























                                                                  placebo   N/A   24 weeks   112     Outpatients diagnosed as having AD by the diagnostic criteria of DSM-IV; CDR of (1) mild or (2)  moderate; MMSE score of 10-26 points; ADAS-J-Cog score of at least 15 points  Patients with neurological signs such as parkinsonism; patients with definite symptoms of depression,  and patients with old had trauma associated with disturbances of consciousness; patients with visual or  hearing impairment or with aphasia who could not undergo the cognitive performance test and patients  with no caregivers to provide assistance in ou
























                          Drugs   Authors:  Homma et al. 41    Setting: Multi-center (54)   donepezil   5 mg/d   24 weeks   116      patients with peptic ulcers




                          Alzheimer     Year:  2000   Country: Japan   NR      Study design: RCT   Sample size: 268      rehabilitation





















             Final Report Update 1     Efficacy/Effectiveness  STUDY:      FUNDING:   RESEARCH OBJECTIVE:      DESIGN:           INTERVENTION:    Dose:     Duration:     Sample size:   INCLUSION:   EXCLUSION:   OTHER MEDICATIONS/  INTERVENTIONS ALLOWED:     Alzheimer's Drugs
   113   114   115   116   117   118   119   120   121   122   123